Bortezomib, lenalidomide, and dexamethasone (VRD) is superior to   lenalidomide, adriamycin, and dexamethasone (RAD) prior to risk-adapted   transplant in newly diagnosed myeloma.

Dokumenttyp:: Meeting Abstract
Autor(en):: Knop, Stefan; Langer, Christian; Engelhardt, Monika Martha; Bassermann, Florian; Schreder, Martin; Muegge, Lars-Olof; Schaefer-Eckart, Kerstin; Blau, Igor W.; Wolleschak, Denise; Reusch, Julia; von Metzler, Ivana; Metzner, Bernd; Dechow, Tobias; Hertenstein, Bernd; Duerk, Heinz; Theurich, Sebastian; Stuebig, Thomas; Kroenke, Jan; Held, Swantje; Einsele, Hermann
Titel:: Bortezomib, lenalidomide, and dexamethasone (VRD) is superior to lenalidomide, adriamycin, and dexamethasone (RAD) prior to risk-adapted transplant in newly diagnosed myeloma.
Zeitschriftentitel:: J Clin Oncol
Jahr:: 2020
Band / Volume:: 38 Suppl S
Heft / Issue:: 15
Print-ISSN:: 0732-183X
TUM Einrichtung:: III. Medizinische Klinik und Poliklinik (Hämatologie / Onkologie)
BibTeX

Vorkommen: